Drug Profile
Amubarvimab/romlusevimab - Brii Biosciences
Alternative Names: Amubarvimab/romlusevimab combination - Brii Biosciences; BRII-196/BRII-198Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator The Third People's Hospital of Shenzhen; Tsinghua University
- Developer Brii Biosciences; National Institute of Allergy and Infectious Diseases; TSB Therapeutics (Beijing) CO.LTD
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 14 Jul 2023 National Institute of Allergy and Infectious Diseases completes a phase III trial in COVID-2019 infections (Combination therapy) in United Kingdom, Nigeria, Uganda, Singapore, Denmark, Spain, Switzerland, Greece, USA, Poland (IV) (NCT04501978) (EudraCT2020-003278-37)
- 20 Jun 2023 National Institute of Allergy and Infectious Diseases (NIAID) completes phase-II/III ACTIV-2 trial in COVID-2019 infections in USA, Argentina, Brazil, Canada, South Africa, Mexico, Philippines and Puerto Rico (IV) (NCT04518410)
- 19 Feb 2023 Updated efficacy data from the phase II Activ-2 trial in COVID-19 infections presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)